Anemia Treatment Market - Growth, Trends, and Forecasts (2022 - 2027)

The Anemia Treatment Market is segmented by Disease Type (Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia, Others) and Geography

Market Snapshot

Anemia Drugs Market Share
Study Period: 2017-2025
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 7.3 %
Anemia Treatment Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Anemia treatment market is expected to witness robust growth over the forecast period which is majorly attributed to the increasing cases of anemia across the globe, increasing pipelines for anemia drugs, and increasing number of women with reproductive age.

The National Institute of Health has stated that anemia affects around one third of the world population and contributes to increased morbidity and mortality, decreased work productivity, and impaired neurological development. The population which is more vulnerable to this disease is the children below age 5 years and the pregannat women. There are effeorts being made to reduce the burden of this disease. For instance, the WHO Global Nutrition Target 2025 on anemia aims to reduce anemia in WRA by 50% by 2025. Hence, with such efforts, there will be an increase in the number of people going for treatemnt and ultimately the market will grow.

Scope of the Report

Anemia is a condition in which a person lacks enough healthy red blood cells to carry adequate oxygen to your body's tissues.

By Type of Disease
Iron Deficiency Anemia
CKD (Chronic Kidney Disease) Anemia
Sickle Cell Anemia
Aplastic Anemia
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Iron Deficiency Anemia to Witness Healthy CAGR Over the Forecast Period

Iron deficiency anemia is the most common type of anemia in which the blood does not have adequate amount of reb blood cells which carry oxygen to the body's tissues. As per the National Institute of Health, Iron Deficiency Anemia is one of the main nutritional deficiency disorders affecting large fractions of the population, particularly such physiological groups as children, menstruating women and pregnant women.

Similarly in the Asian countries such as India and China, iron deficiency anemia is posing a burden with increasing prevalence of the disease across the women. Therefore, it is believed that the segment will witness a healthy growth over the forecast period.

Anemia Treatment Market Analysis

North America Dominates the Market

North America dominated the overall anemia treatment market, with the United States being the major contributor to the market. According to the study of Mechanisms of Ageing and Development, 2018, iron deficiency anemia is highly prevalent in pregnant women and children. In the United States, the prevalence rate of iron deficiency anemia was found to be around 10% in women of child bearing age while one third of the children (12 months to 36 months) are likely to suffer from it. Moreover, the increasing product approvals related to anemia treatment are expected to be the major contributor in the market. For instance, recently, Pharmacosmos AS, recieved an US FDA approval for it's product "Monoferric" for the treatment of iron deficiency anemia. Hence, the high prevalence rate of anemia is expected to boost the growth of the market in North America.

Anemia Treatment Market Revenue

Competitive Landscape

The market for anemia treatment is moderately competitive with a presence of most of the international companies. Companies are focusing on developing the drugs or therapies to treat anemia. Entry to this market is difficult as the company has to go through stringent regulations. However, it is believed that in the future, few small to mid sized companies will be entering in the market and gain a substantial share.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Cases of Anemia Across the Globe

      2. 4.2.2 Increasing Number of Women With Reproductive Age

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness About the Treatment in Developing Regions

      2. 4.3.2 High Cost of Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Type of Disease

      1. 5.1.1 Iron Deficiency Anemia

      2. 5.1.2 CKD (Chronic Kidney Disease) Anemia

      3. 5.1.3 Sickle Cell Anemia

      4. 5.1.4 Aplastic Anemia

      5. 5.1.5 Others

    2. 5.2 Geography

      1. 5.2.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.2.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.2.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.2.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Akebia Therapeutics

      2. 6.1.2 Bluebird Bio, Inc.

      3. 6.1.3 GlaxoSmithKline Plc.

      4. 6.1.4 Global Blood Therapeutics, Inc.

      5. 6.1.5 Pieris Pharmaceuticals, Inc.

      6. 6.1.6 Sanofi

      7. 6.1.7 Takeda Pharmaceutical Company

      8. 6.1.8 Allergan

      9. 6.1.9 Pharmacosmos A/S

      10. 6.1.10 Pfizer Inc.

      11. 6.1.11 AMAG Pharmaceuticals Inc.

    2. *List Not Exhaustive

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Anemia Treatment Market market is studied from 2017 - 2025.

The Anemia Treatment Market is growing at a CAGR of 7.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2019.

AMAG Pharmaceuticals, Inc., Sanofi, Pfizer Inc., Allergan (AbbVie Inc.), PHARMACOSMOS A/S are the major companies operating in Anemia Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!